Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients

Second-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients failing imatinib. Direct comparisons between dasatinib a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiribelli, Mario, Bonifacio, Massimiliano, Binotto, Gianni, Iurlo, Alessandra, Cibien, Francesca, Maino, Elena, Guella, Anna, Festini, Gianluca, Minotto, Claudia, De Biasi, Ercole, De Marchi, Federico, Scaffidi, Luigi, Frison, Luca, Bucelli, Cristina, Medeot, Marta, Calistri, Elisabetta, Sancetta, Rosaria, Stulle, Manuela, Orofino, Nicola, Krampera, Mauro, Gherlinzoni, Filippo, Semenzato, Gianpietro, Pizzolo, Giovanni, Ambrosetti, Achille, Fanin, Renato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865665/
https://www.ncbi.nlm.nih.gov/pubmed/29581839
http://dx.doi.org/10.18632/oncotarget.24478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865665/
https://www.ncbi.nlm.nih.gov/pubmed/29581839
http://dx.doi.org/10.18632/oncotarget.24478

Ejemplares similares